Clinical Trials Sponsored by Emerald Health Pharmaceuticals

Total 448 results

Emerald Health Pharmaceuticals

Suspended

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis

United States, Puerto Rico, Australia, New Zealand
Emerald Health Pharmaceuticals

Completed

To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Healthy

Australia
Emerald Health Pharmaceuticals

Suspended

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

United States, Australia
Ronaldo de Matos Esmeraldo, MD
Novartis Pharmaceuticals

Completed

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Cytomegalovirus Infections | Transplantation Infection

Brazil
Overseas Pharmaceuticals, Ltd.
Guangzhou Health Start Pharmaceutical Techology Co.,Ltd

Not yet recruiting

An Comparative Pharmacokinetic Study of Amlodipine Besylate Controlled-release Tablets,China in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions

Hypertension

China
Tetraphase Pharmaceuticals, Inc.
PRA Health Sciences

Completed

Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers (BAL)

Healthy Subjects

United Kingdom
CyDex Pharmaceuticals, Inc.
Syneos Health; Ligand Pharmaceuticals

Completed

Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection

Contrast-induced Nephropathy | Coronary Angiography

Canada
Primus Pharmaceuticals
Illumination Health

Recruiting

Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.

Lumbar Spinal Stenosis | Sciatica Acute

United States
Alexion Pharmaceuticals
Syneos Health

Terminated

A Study of ALXN1830 in Healthy Adult Participants

Healthy

New Zealand
Fraser Health
Novartis Pharmaceuticals

Unknown

Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs)

Influenza

Canada
CHRISTUS Health
Pharco Pharmaceuticals

Not yet recruiting

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients. (SeCOVID)

Covid19

United States
Northwell Health
Regeneron Pharmaceuticals

Withdrawn

Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail

COVID-19 | Organ Transplant

United States
Marius Pharmaceuticals
Syneos Health

Completed

Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

Hypogonadism, Male

United States
Avanir Pharmaceuticals
Syneos Health

Completed

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS (STAR)

Pseudobulbar Affect (PBA)

United States, Argentina, Brazil
Northwell Health
Jazz Pharmaceuticals

Recruiting

Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).

Electrical Status Epilepticus of Slow-Wave Sleep

United States
Marius Pharmaceuticals
Syneos Health

Completed

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

Hypogonadism, Male

United States
Regeneron Pharmaceuticals
Syneos Health

Withdrawn

Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

Anemia | Chronic Kidney Disease

United States
BioMarin Pharmaceutical
Syneos Health

Recruiting

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding (PALomino)

Phenylketonuria, Maternal

Germany, United States, Italy
Tetraphase Pharmaceuticals, Inc.
Department of Health and Human Services

Completed

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women (BAL)

Normal Drug Tolerance

United States
Hikma Pharmaceuticals LLC
Syneos Health

Completed

Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan (PASSRRA)

Rheumatoid Arthritis

Jordan
FORUM Pharmaceuticals Inc
Syneos Health

Completed

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Ukraine, United Kingdom, Germany, Spain, Argentina, Canada, Singapore, Russian Federation, Italy, Mexico, Colombia, Australia, Belgium, Poland, Romania
FORUM Pharmaceuticals Inc
Syneos Health

Completed

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

Central Nervous System Diseases | Schizophrenia | Cognition

United States, Russian Federation, Ukraine, Serbia
JHP Pharmaceuticals LLC
Syneos Health

Unknown

Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2) (02)

Tuberculosis Identification.
JHP Pharmaceuticals LLC
Syneos Health

Unknown

Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)

Tuberculosis Infection

United States
FORUM Pharmaceuticals Inc
Syneos Health

Completed

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Central Nervous System Diseases | Alzheimer's Disease

United States
Tioga Pharmaceuticals
RTI Health Solutions

Terminated

Asimadoline for the Treatment of Post-Operative Ileus

Post-Operative Ileus

United States
Tioga Pharmaceuticals
RTI Health Solutions

Completed

Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Alexion Pharmaceuticals, Inc.
Syneos Health

Completed

Study of ALXN1820 in Healthy Adult Participants

Healthy

Australia, United Kingdom
Olix Pharmaceuticals, Inc.
Alira Health

Completed

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

Hypertrophic Scar

United States
Spectrum Health Hospitals
Primus Pharmaceuticals

Withdrawn

Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting

Varicose Veins | Venous Insufficiency of Leg | Venous Reflux | Lower Extremity Edema Chronic

United States
NYU Langone Health
Ferring Pharmaceuticals

Completed

Effectiveness Trial for Evaluating IAHA for PFPS (PFPS)

Patellofemoral Pain Syndrome

United States
OPKO Health, Inc.
Elan Pharmaceuticals

Completed

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia (DS201)

Down Syndrome

United States
OPKO Health, Inc.
Elan Pharmaceuticals

Completed

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Spain, United Kingdom
OPKO Health, Inc.
Elan Pharmaceuticals

Terminated

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Bipolar 1 Disorder

United States, Bulgaria, Canada, Czechia, France, Poland, Romania, Spain, Turkey
Atlantic Health System
Cornerstone Pharmaceuticals

Unknown

A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

United States
Supernus Pharmaceuticals, Inc.
Melbourne Health

Completed

Bioavailability, Safety, and Tolerability of BIS-001 ER

Epilepsy, Complex Partial

Australia
NYU Langone Health
OSI Pharmaceuticals

Terminated

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Ovarian Cancer

United States
NYU Langone Health
Novartis Pharmaceuticals

Completed

RAD001 Plus Carboplatin in Breast Cancer Patients

Breast Cancer

United States
Tioga Pharmaceuticals
RTI Health Solutions

Completed

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Diarrhea Predominant Irritable Bowel Syndrome

United States
Threshold Pharmaceuticals
PRA Health Sciences

Terminated

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia | Enlarged Prostate

Hungary, Poland, Germany, Italy
Neurim Pharmaceuticals Ltd.
Syneos Health

Active, not recruiting

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Alzheimer's Disease

United States, Canada
Eloxx Pharmaceuticals, Inc.
Syneos Health

Completed

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

Impaired Renal Function

United States
OPKO Health, Inc.
Elan Pharmaceuticals

Terminated

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Spain, United Kingdom
Threshold Pharmaceuticals
PRA Health Sciences

Completed

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Cubist Pharmaceuticals LLC
Syneos Health

Terminated

Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

Renal Impairment

United States
JHP Pharmaceuticals LLC
Syneos Health

Unknown

Equivalence Study of Specificity of PPD (03)

Tuberculosis Infection

United States
Ochsner Health System
Cumberland Pharmaceuticals

Unknown

Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy (NAC)

Nephropathy

United States
University Health Network, Toronto
Novartis Pharmaceuticals

Completed

Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms

Myelofibrosis (MF) | Myeloproliferative Neoplasms (MPN) | Polycythemia Vera (PV) | Essential Thrombocythemia (ET)

Canada
University Health Network, Toronto
Novartis Pharmaceuticals

Completed

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck | Locoregionally Advanced

Canada
University Health Network, Toronto
Novartis Pharmaceuticals

Completed

A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung (MEK162)

Lungcancer

Canada

Clinical Trials Sponsored by Emerald Health Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations